Momilactone B
Based on 1 Customer Validation
Momilactone B is an inhibitor of α-amylase and α-glucosidase, with an IC50 of 146.85 μg/mL against Aspergillus oryzae α-amylase and an IC50 of 612.03 μg/mL against Saccharomyces cerevisiae α-glucosidase. Momilactone B upregulates the expression of p21Waf1/Cip1, reduces the kinase activity of Cdk4 and Cdk6, induces cell cycle arrest and apoptosis in cancer cells, and triggers irreversible cell death via cell membrane damage. Momilactone B inhibits the growth of neighboring plant species and serves as a major contributing factor to the allelopathy of rice. Momilactone B can be used in studies related to rice allelopathy, type 2 diabetes, colon cancer and leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.47%
- CAS. Nr.: 51415-08-8
- Formel: C20H26O4
- Molecular Weight:330.42
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
α‑glucosidase 612.03 μg/mL (IC50) |
CDK4 |
CDK6 |
Momilactone B potently inhibits α-amylase from Aspergillus oryzae, with an IC50 of 146.85 µg/mL, and its inhibitory effect is positively correlated with concentration; it also potently inhibits α-glucosidase from Saccharomyces cerevisiae, with an IC50 of 612.03 µg/mL[1].
Momilactone B (0.5-10 μM; 24 h) reduces the viability of human colon cancer HT-29 and SW620 cells in a dose-dependent manner[2].
Momilactone B (0.5-5 μM; 72 h) induces dose-dependent cell membrane damage and irreversible cell death in human colon cancer HT-29 and SW620 cells[2].
Momilactone B (0.5-5 μM; 18 h) inhibits colony formation in human colon cancer HT-29 and SW620 cells[2].
Momilactone B (0.25-2 µg/mL; 48 h) reduces the viability of human monocytic leukemia U937 cells in a concentration-dependent manner[4].
Momilactone B potently inhibits root and shoot growth of barnyard grass, with IC50 values of 6.1 μM and 6.3 μM, respectively; moreover, at concentrations that produce phytotoxicity against barnyard grass, its growth inhibitory effect on rice seedlings is negligible[3].
Momilactone B potently inhibits root and shoot growth of E. colonum, with IC50 values of 5.0 μM and 12.5 μM, respectively[3].
Momilactone B (0.66-3.84 μM; 4 days) is secreted by rice seedlings, and its contribution rate to the growth inhibition of barnyard grass reaches 58.8%-81.9%. Moreover, a significant correlation exists between the concentration of Momilactone B and allelopathic activity among different rice varieties[3].
Momilactone B (0.25-1.5 µg/mL; 48 h) concentration-dependently arrests human monocytic leukemia U937 cells at the G1 phase of the cell cycle, and reduces the proportion of cells entering the S and G2/M phases. It also induces chromatin condensation and fragmentation, two markers of apoptosis, in human monocytic leukemia U937 cells in a concentration-dependent manner[4].
Momilactone B (0.25-2 µg/mL; 48 h) induces apoptosis in human monocytic leukemia U937 cells in a concentration-dependent manner, and induces cleavage of the apoptosis marker PARP in human monocytic leukemia U937 cells also in a concentration-dependent manner[4].
Momilactone B (0.25-1.5 µg/mL; 48 h) slightly reduces the protein level of cyclin E in human monocytic leukemia U937 cells, induces p21 expression in a p53-independent manner, inhibits the kinase activities of Cdk4 and Cdk6, dephosphorylates pRB, and enhances the binding of pRB to E2F-1 and E2F-4[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human colon cancer HT-29, SW620 cells
-
Concentration:0.5, 1, 5, 10 μM
-
Incubation Time:24 h
-
Result:Reduced cell viability in a dose-dependent manner.
Decreased cell viability by 20-50% compared to untreated control cells.
Showed significant reduction at all tested concentrations.
-
Cell Line:human colon cancer HT-29, SW620 cells
-
Concentration:0.5, 1, 5 μM
-
Incubation Time:72 h
-
Result:Increased LDH release (indicating cell membrane damage) in both cell lines compared to controls.
Increased cell damage by 20-30% compared to controls.
Induced significant increase in LDH release in HT-29 cells and SW620 cells.
-
Cell Line:human colon cancer HT-29, SW620 cells
-
Concentration:0.5, 1, 5 μM
-
Incubation Time:18 h
-
Result:Inhibited colony formation in a dose-dependent manner.
Reduced survival in HT-29 cells at 0.5 μM, with significant reduction.
Reduced survival significantly in SW620 cells.
Had an IC50 of less than 1 mM for inhibition of colony formation in both cell lines.
-
Cell Line:human monocytic leukemia U937 cells
-
Concentration:0.25, 0.5, 1, 1.5, 2 µg/mL
-
Incubation Time:48 h
-
Result:Reduced U937 cell viability to ~90% at 0.5 µg/mL, ~70% at 1 µg/mL, ~55% at 1.5 µg/mL, and ~35% at 2 µg/mL.
Caused statistically significant viability reduction at all concentrations ≥0.5 µg/mL.
-
Cell Line:human monocytic leukemia U937 cells
-
Concentration:0.25, 0.5, 1, 1.5 µg/mL
-
Incubation Time:48 h
-
Result:Induced dose-dependent elevation of G1 phase cell proportion and reductions in S and G2/M phase cell proportions compared with control group.
-
Cell Line:human monocytic leukemia U937 cells
-
Concentration:0.25, 0.5, 1, 1.5, 2 µg/mL
-
Incubation Time:48 h
-
Result:Induced concentration-dependent increases in nuclear chromatin condensation and fragmentation, characteristic morphological markers of apoptosis.
Induced concentration-dependent DNA fragmentation with ladder-like gel bands, and raised apoptotic cell percentage in a dose-dependent manner.
Caused statistically significant rise of apoptotic cell percentage at concentrations ≥1 µg/mL versus controls.
-
Cell Line:human monocytic leukemia U937 cells
-
Concentration:0.25, 0.5, 1, 1.5, 2 µg/mL
-
Incubation Time:48 h
-
Result:Caused concentration-dependent cleavage of the 116 kDa pro-form PARP to its inactive 85 kDa fragment, a marker of caspase-mediated apoptosis.
-
Cell Line:human monocytic leukemia U937 cells
-
Concentration:0.25, 0.5, 1, 1.5 µg/mL
-
Incubation Time:48 h
-
Result:Reduced cyclin E protein levels, upregulated p21 expression via p53-independent pathway, suppressed Cdk4/Cdk6 kinase activity, dephosphorylated pRB, and promoted pRB-E2F-1/E2F-4 binding in U937 cells.
Chemical Information
-
CAS. Nr. 51415-08-8
-
Appearance Solid
-
Molecular Weight 330.42
-
Formel C20H26O4
-
Color White to off-white
-
SMILES
O=C1O[C@]2([H])C=C3[C@](CC[C@@](C)(C=C)C3)([H])[C@@]4(CC5)[C@]2([H])[C@]1(C)[C@@]5(O)OC4
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Reinheit & Dokumentation
-
Data Sheet (286 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Quan NV, et al. Momilactones A and B Are α-Amylase and α-Glucosidase Inhibitors. Molecules (Basel, Switzerland). 2019 Jan 29;24(3):482. [Content Brief]
[2]. Kim SJ, et al. Cytotoxic and antitumor activity of momilactone B from rice hulls. Journal of agricultural and food chemistry. 2007 Mar 07;55(5):1702-6. [Content Brief]
[4]. Park C, et al. Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1/Cip1. Oncology reports. 2014 Apr;31(4):1653-60. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Momilactone B Related Classifications
HY-N11852 Related Classifications
Powered by Bioz